keyword
https://read.qxmd.com/read/38582266/idebenone-ameliorates-statin-induced-myotoxicity-in-atherosclerotic-apoe-mice-by-reducing-oxidative-stress-and-improving-mitochondrial-function
#1
JOURNAL ARTICLE
Wenfei Yu, Wenjing Wu, Dandan Zhao, Rui ZhangMD, Kai Shao, Haoyang Liu, Chuanzhu Yan, Pengfei Lin
Statins are the first line of choice for the treatment for atherosclerosis, but their use can cause myotoxicity, a common side effect that may require dosage reduction or discontinuation. The exact mechanism of statin-induced myotoxicity is unknown. Previous research has demonstrated that the combination of idebenone and statin yielded superior anti-atherosclerotic outcomes. Here, we investigated the mechanism of statin-induced myotoxicity in atherosclerotic ApoE-/- mice and whether idebenone could counteract it...
April 4, 2024: Biochimica et Biophysica Acta. Molecular Basis of Disease
https://read.qxmd.com/read/38263197/the-temporal-progression-of-retinal-degeneration-and-early-stage-idebenone-treatment-in-the-pde6b-rd1-rd1-mouse-model-of-retinal-dystrophy
#2
JOURNAL ARTICLE
Lei Zhang, Wei Liu, Hai-Yan Wang, Wei Qiang, Ru Wang, Zhi-Li Cui, Zuo-Ming Zhang
Photoreceptor cell death, primarily through apoptosis, related to retinal disorders like retinitis pigmentosa (RP), would result in vision loss. The pathological processes and crucial mutant conditions preceding photoreceptor cell demise are not well understood. This study aims to conduct an in-depth examination of early-stage changes in the widely utilized Pde6brd1/rd1 (rd1) mouse model, which has Pde6b gene mutations representing autosomal recessive RP disorder. We investigated the morphology and ultrastructure of retinal cells, including second-order neurons, during the initial phase of disease progression...
January 23, 2024: Scientific Reports
https://read.qxmd.com/read/38016117/leber-s-hereditary-optic-neuropathy-update-on-the-novel-genes-and-therapeutic-options
#3
JOURNAL ARTICLE
Jui-Lin Hu, Chih-Chien Hsu, Yu-Jer Hsiao, Yi-Ying Lin, Wei-Yi Lai, Yu-Hao Liu, Chia-Lin Wang, Yu-Ling Ko, Ming-Long Tsai, Huan-Chin Tseng, Yueh Chien, Yi-Ping Yang
A maternal inheritance disorder called Leber's hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA disorder. In most studies, there are more male patients than female patients, which contradicts the usual pattern in mitochondrial hereditary diseases. This suggests that nuclear DNA (nDNA) may influence the degeneration of retinal ganglion cells (RGCs) in LHON. The primary cause of this is dysfunction in complex I of the electron transport chain, leading to ineffective ATP production...
November 28, 2023: Journal of the Chinese Medical Association: JCMA
https://read.qxmd.com/read/37708949/the-parkinson-s-disease-associated-mutation-lrrk2-g2385r-alters-mitochondrial-biogenesis-via-the-pgc-1%C3%AE-tfam-pathway
#4
JOURNAL ARTICLE
Jian Xue, Jinbao Zhang, Jinru Zhang, Junyi Liu, Fen Wang, Kai Li, Chunfeng Liu
Mutations in the Leucine-rich repeat protein kinase 2 (LRRK2) gene are the most frequent cause of familial Parkinson's disease (PD). Although LRRK2 has been extensively studied, the pathogenic mechanism of the LRRK2 G2385R mutation, which is most common in Asian populations, especially in the Chinese Han population, remains unclear. In this study, we demonstrated that the LRRK2 G2385R mutation in HEK293T cells led to a reduction in cellular PGC-1α protein expression and inhibition of mitochondrial biogenesis through the PGC-1α-TFAM pathway...
September 12, 2023: Mitochondrion
https://read.qxmd.com/read/36813316/mitochondrial-optic-neuropathies
#5
REVIEW
Valerio Carelli, Chiara La Morgia, Patrick Yu-Wai-Man
Mitochondrial optic neuropathies have a leading role in the field of mitochondrial medicine ever since 1988, when the first mutation in mitochondrial DNA was associated with Leber's hereditary optic neuropathy (LHON). Autosomal dominant optic atrophy (DOA) was subsequently associated in 2000 with mutations in the nuclear DNA affecting the OPA1 gene. LHON and DOA are both characterized by selective neurodegeneration of retinal ganglion cells (RGCs) triggered by mitochondrial dysfunction. This is centered on respiratory complex I impairment in LHON and defective mitochondrial dynamics in OPA1-related DOA, leading to distinct clinical phenotypes...
2023: Handbook of Clinical Neurology
https://read.qxmd.com/read/36716943/geneye24-novel-rapid-screening-test-for-the-top-3-leber-s-hereditary-optic-neuropathy-pathogenic-sequence-variants
#6
JOURNAL ARTICLE
Sara Martins, Maria João Santos, Márcia Teixeira, Luísa Diogo, Maria do Carmo Macário, João Pedro Marques, Pedro Fonseca, Manuela Grazina
Leber's Hereditary Optic Neuropathy (LHON) has been mainly (90-95%) associated to one of three variants: m.3460G>A, m.11778G>A, m.14484T>C. Herein, a screening method was developed for its detection, supporting clinical/therapeutics decision. It relies on real-time PCR with High-Resolution Melting (HRM) analysis. Variant classification is made using HRM Software and quality controls. Ninety-four samples were analyzed. All samples were correctly assigned: 58 wild-type, 35 positive for m.11778G>A, 6 positive for m...
January 27, 2023: Mitochondrion
https://read.qxmd.com/read/36529474/-medical-treatments-in-leber-s-hereditary-optic-neuropathy
#7
REVIEW
R Hage
Leber's hereditary optic neuropathy (LHON) is a maternally inherited disease caused by a mutation of mitochondrial DNA. LHON targets retinal ganglion cells (RGC), whose axons form the optic nerve. The mutation that leads to LHON is silent until an unknown trigger causes dysfunction of complex I in the mitochondria of RGC. This results in discontinuation of RGC energy production and, eventually, RGC apoptosis. Patients experience bilateral sequential central scotoma over the course of a few months, with a minority recovering some vision more than 1 year after the onset of visual loss...
November 2022: Journal Français D'ophtalmologie
https://read.qxmd.com/read/36191230/cgg-repeat-expansion-in-notch2nlc-causes-mitochondrial-dysfunction-and-progressive-neurodegeneration-in-drosophila-model
#8
JOURNAL ARTICLE
Jiaxi Yu, Tongling Liufu, Yilei Zheng, Jin Xu, Lingchao Meng, Wei Zhang, Yun Yuan, Daojun Hong, Nicolas Charlet-Berguerand, Zhaoxia Wang, Jianwen Deng
Neuronal intranuclear inclusion disease (NIID) is a neuromuscular/neurodegenerative disease caused by the expansion of CGG repeats in the 5' untranslated region (UTR) of the NOTCH2NLC gene. These repeats can be translated into a polyglycine-containing protein, uN2CpolyG, which forms protein inclusions and is toxic in cell models, albeit through an unknown mechanism. Here, we established a transgenic Drosophila model expressing uN2CpolyG in multiple systems, which resulted in progressive neuronal cell loss, locomotor deficiency, and shortened lifespan...
October 11, 2022: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/35858578/pathological-mitophagy-disrupts-mitochondrial-homeostasis-in-leber-s-hereditary-optic-neuropathy
#9
JOURNAL ARTICLE
Alberto Danese, Simone Patergnani, Alessandra Maresca, Camille Peron, Andrea Raimondi, Leonardo Caporali, Saverio Marchi, Chiara La Morgia, Valentina Del Dotto, Claudia Zanna, Angelo Iannielli, Alice Segnali, Ivano Di Meo, Andrea Cavaliere, Magdalena Lebiedzinska-Arciszewska, Mariusz R Wieckowski, Andrea Martinuzzi, Milton N Moraes-Filho, Solange R Salomao, Adriana Berezovsky, Rubens Belfort, Christopher Buser, Fred N Ross-Cisneros, Alfredo A Sadun, Carlo Tacchetti, Vania Broccoli, Carlotta Giorgi, Valeria Tiranti, Valerio Carelli, Paolo Pinton
Leber's hereditary optic neuropathy (LHON), a disease associated with a mitochondrial DNA mutation, is characterized by blindness due to degeneration of retinal ganglion cells (RGCs) and their axons, which form the optic nerve. We show that a sustained pathological autophagy and compartment-specific mitophagy activity affects LHON patient-derived cells and cybrids, as well as induced pluripotent-stem-cell-derived neurons. This is variably counterbalanced by compensatory mitobiogenesis. The aberrant quality control disrupts mitochondrial homeostasis as reflected by defective bioenergetics and excessive reactive oxygen species production, a stress phenotype that ultimately challenges cell viability by increasing the rate of apoptosis...
July 19, 2022: Cell Reports
https://read.qxmd.com/read/35090586/human-ipsc-model-reveals-a-central-role-for-nox4-and-oxidative-stress-in-duchenne-cardiomyopathy
#10
JOURNAL ARTICLE
Robin Duelen, Domiziana Costamagna, Guillaume Gilbert, Liesbeth De Waele, Nathalie Goemans, Kaat Desloovere, Catherine M Verfaillie, Karin R Sipido, Gunnar M Buyse, Maurilio Sampaolesi
Duchenne muscular dystrophy (DMD) is a progressive muscle disorder caused by mutations in the Dystrophin gene. Cardiomyopathy is a major cause of early death. We used DMD-patient-specific human induced pluripotent stem cells (hiPSCs) to model cardiomyopathic features and unravel novel pathologic insights. Cardiomyocytes (CMs) differentiated from DMD hiPSCs showed enhanced premature cell death due to significantly elevated intracellular reactive oxygen species (ROS) resulting from depolarized mitochondria and increased NADPH oxidase 4 (NOX4)...
January 17, 2022: Stem Cell Reports
https://read.qxmd.com/read/35039479/idebenone-improves-motor-dysfunction-learning-and-memory-by-regulating-mitophagy-in-mptp-treated-mice
#11
JOURNAL ARTICLE
Junqiang Yan, Wenjie Sun, Mengmeng Shen, Yongjiang Zhang, Menghan Jiang, Anran Liu, Hongxia Ma, Xiaoyi Lai, Jiannan Wu
The progression of Parkinson's disease (PD) is often accompanied by the loss of substantia nigra dopaminergic neurons, mitophagy damage, learning, and memory impairment. Idebenone is a therapeutic drug that targets the mitochondria of neurodegenerative diseases, but its role in Parkinson's disease and its pathological mechanism are still unclear. The purpose of this study was to investigate whether idebenone could improve behavioral disorders, especially motor, learning, and memory disorders, in mouse PD models and to explore its molecular mechanism...
January 17, 2022: Cell Death Discovery
https://read.qxmd.com/read/34915201/altering-neuronal-circuitry-with-4-aminopyridine-for-visual-improvement-in-leber-s-hereditary-optic-neuropathy-lhon
#12
JOURNAL ARTICLE
Jane W Chan, William Sultan, Rustum Karanjia, Alfredo A Sadun
In this retrospective, interventional, longitudinal small case series, we looked at the visual effects of pharmacologic intervention with 4-aminopyridine (4-AP) in chronic Leber's Hereditary Optic Neuropathy (LHON) patients who are non-responders to idebenone. We illustrate, as examples, the visual progression of three LHON patients with 4-AP as add-on therapy to idebenone. Each patient had a different primary LHON mutation and was treated with idebenone within one year of onset. No response to idebenone at 300 mg orally three times a day ranged from less than one year to 2...
December 13, 2021: Mitochondrion
https://read.qxmd.com/read/34431574/pathologically-responsive-mitochondrial-gene-therapy-in-an-allotopic-expression-independent-manner-cures-leber-s-hereditary-optic-neuropathy
#13
JOURNAL ARTICLE
Yi Wang, Li-Fan Hu, Peng-Fei Cui, Lian-Yu Qi, Lei Xing, Hu-Lin Jiang
Leber's hereditary optic neuropathy (LHON) is a rare inherited blindness caused by mutations in the mitochondrial DNA (mtDNA). The disorder is untreatable and tricky, as the existing chemotherapeutic agent Idebenone alleviates symptoms rather than overcoming the underlying cause. Although some studies have made progress on allotopic expression for LHON, in situ mitochondrial gene therapy remains challenging, which may simplify delivery procedures to be a promising therapeutic for LHON. LHON becomes more difficult to manage in the changed mitochondrial microenvironment, including increasing reactive oxygen species (ROS) and decreasing mitochondrial membrane potential (MMP)...
October 2021: Advanced Materials
https://read.qxmd.com/read/33924642/therapeutic-potential-and-immunomodulatory-role-of-coenzyme-q-10-and-its-analogues-in-systemic-autoimmune-diseases
#14
REVIEW
Chary López-Pedrera, José Manuel Villalba, Alejandra Mª Patiño-Trives, Maria Luque-Tévar, Nuria Barbarroja, Mª Ángeles Aguirre, Alejandro Escudero-Contreras, Carlos Pérez-Sánchez
Coenzyme Q10 (CoQ10 ) is a mitochondrial electron carrier and a powerful lipophilic antioxidant located in membranes and plasma lipoproteins. CoQ10 is endogenously synthesized and obtained from the diet, which has raised interest in its therapeutic potential against pathologies related to mitochondrial dysfunction and enhanced oxidative stress. Novel formulations of solubilized CoQ10 and the stabilization of reduced CoQ10 (ubiquinol) have improved its bioavailability and efficacy. Synthetic analogues with increased solubility, such as idebenone, or accumulated selectively in mitochondria, such as MitoQ, have also demonstrated promising properties...
April 13, 2021: Antioxidants (Basel, Switzerland)
https://read.qxmd.com/read/33744462/complex-i-protein-ndufs2-is-vital-for-growth-ros-generation-membrane-integrity-apoptosis-and-mitochondrial-energetics
#15
JOURNAL ARTICLE
Aloka B Bandara, David A Brown, Joshua C Drake, Carissa C James, James W Smyth
Complex I is the largest and most intricate of the protein complexes of mitochondrial electron transport chain (ETC). This L-shaped enzyme consists of a peripheral hydrophilic matrix domain and a membrane-bound orthogonal hydrophobic domain. The interfacial region between these two arms is known to be critical for binding of ubiquinone moieties and has also been shown to be the binding site of Complex I inhibitors. Knowledge on specific roles of the ETC interfacial region proteins is scarce due to lack of knockout cell lines and animal models...
March 17, 2021: Mitochondrion
https://read.qxmd.com/read/33498409/novel-short-chain-quinones-to-treat-vision-loss-in-a-rat-model-of-diabetic-retinopathy
#16
JOURNAL ARTICLE
Abraham Daniel, Dino Premilovac, Lisa Foa, Zikai Feng, Krupali Shah, Qianyi Zhang, Krystel L Woolley, Nicole Bye, Jason A Smith, Nuri Gueven
Diabetic retinopathy (DR), one of the leading causes of blindness, is mainly diagnosed based on the vascular pathology of the disease. Current treatment options largely focus on this aspect with mostly insufficient therapeutic long-term efficacy. Mounting evidence implicates mitochondrial dysfunction and oxidative stress in the central etiology of DR. Consequently, drug candidates that aim at normalizing mitochondrial function could be an attractive therapeutic approach. This study compared the mitoprotective compounds, idebenone and elamipretide, side-by-side against two novel short-chain quinones (SCQs) in a rat model of DR...
January 20, 2021: International Journal of Molecular Sciences
https://read.qxmd.com/read/31640150/targeting-nrf2-for-the-treatment-of-friedreich-s-ataxia-a-comparison-among-drugs
#17
JOURNAL ARTICLE
Sara Petrillo, Jessica D'Amico, Piergiorgio La Rosa, Enrico Silvio Bertini, Fiorella Piemonte
NRF2 (Nuclear factor Erythroid 2-related Factor 2) signaling is impaired in Friedreich's Ataxia (FRDA), an autosomal recessive disease characterized by progressive nervous system damage and degeneration of nerve fibers in the spinal cord and peripheral nerves. The loss of frataxin in patients results in iron sulfur cluster deficiency and iron accumulation in the mitochondria, making FRDA a fatal and debilitating condition. There are no currently approved therapies for the treatment of FRDA and molecules able to activate NRF2 have the potential to induce clinical benefits in patients...
October 21, 2019: International Journal of Molecular Sciences
https://read.qxmd.com/read/31605306/leber-s-hereditary-optic-neuropathy-as-a-promising-disease-for-gene-therapy-development
#18
JOURNAL ARTICLE
Cuneyt Karaarslan
Leber's hereditary optic neuropathy (LHON) is a relatively common, rapidly progressing inherited optic neuropathy wherein LHON-affected eyes undergo optic nerve atrophy due to retinal ganglion cell (RGC) loss. It is a maternally inherited (or sporadic) mitochondrial disorder caused primarily by mutations in genes that encode components of respiratory complex (RC)1 in mitochondria. Mitochondrial deficiency of RC1 compromises ATP production and oxidative stress management in RGCs. The most common LHON-causing mutations are 11778G>A, 3460G>A, and 14484T>C point mutations in MT-ND4, MT-ND1, and MT-ND6...
December 2019: Advances in Therapy
https://read.qxmd.com/read/31445917/cardioprotective-effects-of-idebenone-do-not-involve-ros-scavenging-evidence-for-mitochondrial-complex-i-bypass-in-ischemia-reperfusion-injury
#19
JOURNAL ARTICLE
Justin B Perry, Grace N Davis, Mitchell E Allen, Marina Makrecka-Kuka, Maija Dambrova, Robert W Grange, Saame Raza Shaikh, David A Brown
Novel therapeutic strategies to treat mitochondrial deficiencies in acute coronary syndromes are needed. Complex I of the mitochondrial electron transport system is damaged following ischemia/reperfusion (I/R) injury. This disruption contributes to aberrant electron transport, diminished bioenergetics, an altered redox environment, and mitochondrial damage involved in tissue injury. In this study, we determined the cardiac and mitochondrial effects of idebenone, a benzoquinone currently in several clinical trials with purported 'antioxidant' effects...
August 22, 2019: Journal of Molecular and Cellular Cardiology
https://read.qxmd.com/read/30171034/idebenone-and-coenzyme-q-10-are-novel-ppar%C3%AE-%C3%AE-ligands-with-potential-for-treatment-of-fatty-liver-diseases
#20
JOURNAL ARTICLE
Jens Tiefenbach, Lilia Magomedova, Jiabao Liu, Arkadiy A Reunov, Ricky Tsai, Neena S Eappen, Rebecca A Jockusch, Corey Nislow, Carolyn L Cummins, Henry M Krause
Current peroxisome proliferator-activated receptor (PPAR)-targeted drugs, such as the PPARγ-directed diabetes drug rosiglitazone, are associated with undesirable side effects due to robust agonist activity in non-target tissues. To find new PPAR ligands with fewer toxic effects, we generated transgenic zebrafish that can be screened in high throughput for new tissue-selective PPAR partial agonists. A structural analog of coenzyme Q10 (idebenone) that elicits spatially restricted partial agonist activity for both PPARα and PPARγ was identified...
August 31, 2018: Disease Models & Mechanisms
keyword
keyword
89842
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.